U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07604324) titled 'A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis' on May 18.
Brief Summary: The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.
Study Start Date: May 25
Study Type: INTERVENTIONAL
Condition:
Dermatitis, Atopic
Intervention:
DRUG: DCY636
Participants will receive DCY636
DRUG: Placebo
Participants will rece...